Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Keros Therapeutics, Inc. - common stock (NQ: KROS )

16.57 -0.14 (-0.84%)
Streaming Delayed Price Updated: 1:25 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Keros Therapeutics, Inc. - common stock

< Previous 1 2 3 Next >
Keros Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - KROS
Via ACCESSWIRE
Where Keros Therapeutics Stands With Analysts
Via Benzinga
Shareholders that lost money on Keros Therapeutics, Inc.(KROS) should contact Levi & Korsinsky about Securities Fraud Investigation - KROS
Via ACCESSWIRE
Levi & Korsinsky Announces an Investigation on Behalf of Keros Therapeutics, Inc. (KROS) Shareholders Who May Have Been Affected by Fraud
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Keros Therapeutics Inc. (NASDAQ: KROS) Near the Top of Equities by Percentage Gain on 1/4
Via Investor Brand Network
Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook
Via Benzinga
Nasdaq Down 50 Points; US Initial Jobless Claims Rise
Via Benzinga
Keros Therapeutics Loses 75% Value In A Single Session - Here's Why
Keros Therapeutics halts high-dose cibotercept treatment in the TROPOS trial after safety concerns, with topline results anticipated in Q2 2025. 
Via Benzinga
Keros Therapeutics Plummets 73% On Unexpected Side Effects In Hypertension Study
The company is continuing to test the lowest dose of its pulmonary arterial hypertension drug. 
Via Investor's Business Daily
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Where Keros Therapeutics Stands With Analysts
Via Benzinga
Recap: Keros Therapeutics Q1 Earnings
Via Benzinga
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
Takeda inks a licensing deal with Keros for elritercept, a late-stage anemia drug, and plans a Phase 3 trial in myelodysplastic syndromes. 
Via Benzinga
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86. 
Via Investor's Business Daily
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
KROS Stock Earnings: Keros Therapeutics Misses EPS for Q2 2024
KROS stock results show that Keros Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth
Keros Therapeutics is advancing novel therapies for hematological and cardiopulmonary disorders via TGF-β signaling regulation. Oppenheimer rates KROS Outperform with a $102 price target. 
Via Benzinga
KROS Stock Earnings: Keros Therapeutics Beats EPS for Q1 2024
KROS stock results show that Keros Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.< 
Via Benzinga
Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose during Thursday’s session following... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the... 
Via Benzinga
Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mostly mixed, with the Dow Jones index gaining more than 100 points on Monday. Here are some other big stocks recording losses in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2023
Via Benzinga
Why American Software Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares jumped 144.5% to $0.7827. 
Via Benzinga
Why Shares of Keros Therapeutics Jumped This Week
The company appointed a new director and an analyst reiterated his position on the stock. 
Via The Motley Fool
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.